Jerusalem, 16 July, 2025 (TPS-IL) — South Korea’s 365mc and Israel’s Raziel Therapeutics have announced a strategic partnership to advance the clinical development of RZL-012, an injectable treatment for localized fat reduction.

The drug, now progressing toward Phase 3 trials, will be evaluated and commercialized in South Korea through the collaboration. 365mc, a leading fat management medical network with 21 branches, will bring clinical, regulatory, and market expertise to the effort. The companies also plan to combine RZL-012 with 365mc’s proprietary LAMS procedure to create an integrated body contouring solution.

As part of the deal, 365mc will invest in Raziel, with support from the Nasdaq-focused Yozma Group.

Pesach Benson

See Full Bio